Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D Schnorr

Showing results (101-110 of 117) with videos related to

Pageof 12
Sort By:
Urological Research|September 27, 2003
Tumor type M2 pyruvate kinase expression in metastatic renal cell carcinomaJ Roigas, S Deger, J Schroeder, et al.
Clinical Chemistry|January 6, 2000
Molecular forms of prostate-specific antigen in malignant and benign prostatic tissue: biochemical and diagnostic implicationsK Jung, B Brux, M Lein, et al.
Radiologia Diagnostica|January 1, 1977
[Lymphography for prostatic carcinoma. 1. Results of leg lymphography]M Lüning, J Plasch, H Schilling, et al.
Clinical Chemistry|January 6, 2000
Ratio of free or complexed prostate-specific antigen (PSA) to total PSA: which ratio improves differentiation between benign prostatic hyperplasia and prostate cancer?K Jung, U Elgeti, M Lein, et al.
Clinical Chemistry|September 1, 1996
Detection of PSA mRNA in blood by RT-PCR does not exclusively indicate prostatic tumor cellsW Henke, M Jung, K Jung, et al.
Free Radical Biology & Medicine|January 1, 1997
Antioxidant enzymes in malignant prostate cell lines and in primary cultured prostatic cellsK Jung, B Seidel, B Rudolph, et al.
European Urology|February 15, 2001
Comparison of the clinical validity of free prostate-specific antigen, alpha-1 antichymotrypsin-bound prostate-specific antigen and complexed prostate-specific antigen in prostate cancer diagnosisM Lein, K Jung, U Elgeti, et al.
Der Urologe. Ausg. A|November 30, 2005
[Kidney transplantation in childhood and adolescence]B Winkelmann, J Thumfart, D Müller, et al.
The Prostate|February 7, 2001
Synthetic inhibitor of matrix metalloproteinases (batimastat) reduces prostate cancer growth in an orthotopic rat modelM Lein, K Jung, D K Le, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|October 23, 1998
High-dose rate interstitial with external beam irradiation for localized prostate cancer--results of a prospective trialS Dinges, S Deger, S Koswig, et al.
Pageof 12

Showing results (101-110 of 117) with videos related to

Sort By:
Pageof 12
Urological Research|September 27, 2003
Tumor type M2 pyruvate kinase expression in metastatic renal cell carcinomaJ Roigas, S Deger, J Schroeder, et al.
Clinical Chemistry|January 6, 2000
Molecular forms of prostate-specific antigen in malignant and benign prostatic tissue: biochemical and diagnostic implicationsK Jung, B Brux, M Lein, et al.
Radiologia Diagnostica|January 1, 1977
[Lymphography for prostatic carcinoma. 1. Results of leg lymphography]M Lüning, J Plasch, H Schilling, et al.
Clinical Chemistry|January 6, 2000
Ratio of free or complexed prostate-specific antigen (PSA) to total PSA: which ratio improves differentiation between benign prostatic hyperplasia and prostate cancer?K Jung, U Elgeti, M Lein, et al.
Clinical Chemistry|September 1, 1996
Detection of PSA mRNA in blood by RT-PCR does not exclusively indicate prostatic tumor cellsW Henke, M Jung, K Jung, et al.
Free Radical Biology & Medicine|January 1, 1997
Antioxidant enzymes in malignant prostate cell lines and in primary cultured prostatic cellsK Jung, B Seidel, B Rudolph, et al.
European Urology|February 15, 2001
Comparison of the clinical validity of free prostate-specific antigen, alpha-1 antichymotrypsin-bound prostate-specific antigen and complexed prostate-specific antigen in prostate cancer diagnosisM Lein, K Jung, U Elgeti, et al.
Der Urologe. Ausg. A|November 30, 2005
[Kidney transplantation in childhood and adolescence]B Winkelmann, J Thumfart, D Müller, et al.
The Prostate|February 7, 2001
Synthetic inhibitor of matrix metalloproteinases (batimastat) reduces prostate cancer growth in an orthotopic rat modelM Lein, K Jung, D K Le, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|October 23, 1998
High-dose rate interstitial with external beam irradiation for localized prostate cancer--results of a prospective trialS Dinges, S Deger, S Koswig, et al.
Pageof 12